Document 0893
 DOCN  M9540893
 TI    [Prevention of Pneumocystis carinii pneumonia associated with HIV
       infection using pentamidine aerosols. Retrospective study of 465 cases]
 DT    9504
 AU    Guinet F; Pialoux G; Trotot P; Chauvelle MT; Feuillie V; Sansonetti P;
       Dupont B; Service des Maladies infectieuses et tropicales, Hopital de;
       l'Institut Pasteur et CHU Necker-Enfants Malades, Paris.
 SO    Presse Med. 1994 Dec 3;23(38):1747-52. Unique Identifier : AIDSLINE
       MED/95132558
 AB    OBJECTIVES: At least 80% of human immunodeficiency virus (HIV)-positive
       patients not given prophylaxis therapy against Pneumocystis carinii
       develop pneumonia, a major cause of morbidity and mortality. We
       therefore retrospectively evaluated prophylaxis protocols given from
       March 1988 to July 1991 at the Pasteur Institute Hospital. METHODS:
       Pentamidine aerosols were prescribed for 456 HIV-positive patients as
       primary or secondary prophylaxis. From March 1988 to November 1989 the
       dose was 4 mg/kg pentamidine mesylate once a month for primary
       prophylaxis and 4 mg/kg twice a month for secondary prophylaxis. From
       November 1989 pentamidine isethionate was given at the dose of 300 mg
       once a month. RESULTS: Tolerance was generally good, treatment had to be
       discontinued in only 2 of the 456 patients due to side effects.
       Pneumocystis carinii pneumonia was diagnosed in 4.9% of the treated
       patients, but in only 2.9% of those who were compliant. Pneumocystis
       carinii pneumonia occurred in very immunodepressed patients and
       radiologically appeared as an interstitial or alveolo-interstitial
       syndrome, often with a macronodular element, in 65% of the patients.
       CONCLUSION: The results of this retrospective study confirm the
       prophylactic value of pentamidine aerosols given after
       trimethoprim-sulfamethoxasol.
 DE    Adult  Aerosols  Aged  AIDS-Related Opportunistic Infections/*PREVENTION
       & CONTROL  English Abstract  Female  Human  Male  Middle Age  Patient
       Compliance  Pentamidine/ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS/*THERAPEUTIC  USE  Pneumonia, Pneumocystis carinii/*PREVENTION &
       CONTROL  Retrospective Studies  Time Factors  Treatment Outcome  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).